Clinical trials
Recruiting Phase 2 trials in Russia
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
47 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2021 | 4 |
| 2022 | 2 |
| 2023 | 7 |
| 2024 | 13 |
| 2025 | 14 |
| 2026 | 4 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Recruiting | 47 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| St. Petersburg State Pavlov Medical University | 6 |
| Biocad | 4 |
| Blokhin's Russian Cancer Research Center | 3 |
| Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 3 |
| Merck Sharp & Dohme LLC | 3 |
| Valenta Pharm JSC | 3 |
| Lomonosov Moscow State University Medical Research and Educational Center | 2 |
| N.N. Petrov National Medical Research Center of Oncology | 2 |
| National Medical Research Radiological Centre of the Ministry of Health of Russia | 2 |
| Nizhny Novgorod Regional Clinical Oncology Center | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Leukemia, Myeloid, Acute | 5 |
| Colorectal Neoplasms | 4 |
| Hodgkin Disease | 4 |
| Myelodysplastic Syndromes | 4 |
| Leukemia, Biphenotypic, Acute | 3 |
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 3 |
| Neoplasms | 3 |
| Arthritis, Juvenile | 2 |
| Coronary Artery Disease | 2 |
| Lung Neoplasms | 2 |
Trials
Showing 1 to 25 of 47. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.